All News

Found 265 articles

• Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy

  2/27/2023

  Zevra Therapeutics, Inc., announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission in connection with the Company’s 2023 Annual Meeting of Stockholders, which is scheduled to take place on April 25, 2023.

• Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results

  2/27/2023

  Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that the Company will host a conference call and live audio webcast on Tuesday, March 7, 2023, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2022.

• Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023

  2/24/2023

  Zevra Therapeutics, Inc. today announced that arimoclomol, the Company’s orally-delivered, first-in-class investigational product candidate being developed as a treatment for Niemann-Pick disease type C (NPC), is being featured in two poster presentations during the 19th Annual WORLDSymposium™ 2023, the annual research conference dedicated to lysosomal diseases being held February 22-26, 2023 in Orlando, Florida, USA.

• Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023

  2/23/2023

  Zevra Therapeutics, Inc. has announced that two abstracts involving clinical research of arimoclomol for the treatment of Niemann-Pick disease type C (NPC), including advancing understanding of NPC disease progression have been accepted for poster presentations at the 19th Annual WORLD Symposium ™ 2023.

• KemPharm Announces Corporate Name Change to Zevra Therapeutics

  2/22/2023

  KemPharm, Inc. announced today that it changed its name to Zevra Therapeutics, Inc. (“Zevra”).

• KemPharm Enhances Senior Management Team

  1/31/2023

  KemPharm, Inc. announced that it has named Daniel Gallo, Ph.D., as Senior Vice President of Medical Affairs and Advocacy, and Abbi Maher, J.D., as Vice President of Legal Affairs.

• KemPharm Issues Letter to Shareholders - January 24, 2023

  1/24/2023

  KemPharm, Inc. today announced that Richard W. Pascoe, Chief Executive Officer of KemPharm, has issued a Letter to Shareholders.

• KemPharm announced its partnership with Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy

  1/18/2023

  KemPharm, Inc. announced its partnership with the Hypersomnia Foundation , which engages, informs and champions the global community to improve the lives of people with idiopathic hypersomnia (IH) and related sleep disorders.

• KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer

  1/11/2023

  KemPharm, Inc. announced the promotions of Sven Guenther, Ph.D., to Chief Scientific Officer, and Christal M.M. Mickle, M.A., to Chief Product Development Officer.

• KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company

  1/9/2023

  KemPharm, Inc. announced changes to its Board of Directors and executive leadership team as part of the Company’s ongoing business transformation initiatives.

• KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)

  12/21/2022

  KemPharm, Inc. today announced the initiation of a Phase 2 clinical trial evaluating KP1077 as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder.

• KemPharm Announces Appointment of Christopher Posner as New Independent Director

  11/29/2022

  KemPharm, Inc. today announced the appointment of Christopher Posner to serve on the Company’s Board of Directors.

• KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)

  11/18/2022

  KemPharm, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted the Orphan Drug Designation to serdexmethylphenidate (SDX), KemPharm’s proprietary prodrug of d-methylphenidate (d-MPH), for the treatment of idiopathic hypersomnia (IH), a rare neurological sleep disorder.

• LadRx Corporation Issues Corporate Update for 3Q22

  11/17/2022

  LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below update to stockholders.

• KemPharm Reports Third Quarter 2022 Results

  11/9/2022

  KemPharm, Inc., a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system and neurodegenerative diseases, lysosomal storage disorders and related treatment areas, reported its financial results for the quarter ended September 30, 2022.

• KemPharm to Report Third Quarter 2022 Financial Results

  11/1/2022

  KemPharm, Inc. today announced that the Company will host a conference call and live audio webcast on Wednesday, November 9, 2022, at 5:00 p.m. ET, to discuss its corporate and financial results for the third quarter 2022.

• KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)

  9/28/2022

  KemPharm, Inc. today announced topline data from its exploratory Phase 1 clinical trial confirming the relative cardiovascular effects and pharmacokinetics of serdexmethylphenidate (SDX) compared to immediate-release and long-acting formulations of Ritalin® (racemic methylphenidate), a commonly prescribed CNS stimulant.

• European Patent Office Awards CytRx Key Patent

  9/7/2022

  CytRx Corporation, a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announced it has been awarded a key patent by the European Patent Office, and that the period for parties to oppose the patent has lapsed without opposition.

• KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  9/1/2022

  KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will deliver a virtual presentation at the H.C. Wainwright 24th Annual Global Investment Conference being held from September 12-14, 2022, in New York, New York.

• 

  Drug Development for Rare Diseases is Littered with Regulatory Roadblocks

  8/19/2022

  The regulatory path for companies developing drugs for rare diseases is often fraught with challenges. KemPharm CEO Travis Mickle discussed just some of these with BioSpace.